Ontario Institute for Cancer Research

John M S Bartlett

Paul Boutros

Melanie Spears

Irina Kalatskaya

Lincoln Stein

Jane Bayani

Marsela Braunstein

Cindy Q Yao

Paul M Krzyzanowksi

There is described herein a method of prognosing endocrine-only treatment in a subject with breast cancer, the method comprising: a) providing a tumor sample of the breast cancer; b) determining the expression level of at least 40 of the genes listed in Table 4 in the tumor sample; c) comparing said expression levels to a reference expression level of the group of genes from control samples from a cohort of subjects; and d) determining the residual risk associated with the breast cancer; wherein a statistically significant difference or similarity in the expression of the group of genes compared to the reference expression level corresponds to a residual risk associated with breast cancer.

Gene signature of residual risk following endocrine treatment in early breast cancer

Growing community of inventors

Toronto, Canada

John M S Bartlett